LEADER 02205nam 22004453 450 001 9911008994903321 005 20231023084510.0 010 $a9789201501226 010 $a9201501226 035 $a(MiAaPQ)EBC30800221 035 $a(CKB)28530701300041 035 $a(Au-PeEL)EBL30800221 035 $a(Exl-AI)30800221 035 $a(OCoLC)1406410879 035 $a(EXLCZ)9928530701300041 100 $a20231023d2023 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPain Palliation of Bone Metastases $eProduction, Quality Control and Dosimetry of Radiopharmaceuticals 205 $a1st ed. 210 1$aVienna :$cInternational Atomic Energy Agency,$d2023. 210 4$dİ2023. 215 $a1 online resource (158 pages) 311 08$a9789201500229 330 $aRadionuclide therapy using bone targeting radiopharmaceuticals is an effective palliative care option to reduce pain associated with advanced disease with bone metastases. Over the last 20 years, suitable therapeutic radionuclides are more widely available, meaning that the benefits of pain palliation therapy could reach more patients. This publication provides a broad overview on the current status of radiopharmaceuticals for bone pain palliation. It covers production of radionuclides, identification of bone seeking carrier molecules, preparation of stable complexes, in vitro and in vivo evaluations and dosimetry studies which are part of the development of these radiopharmaceuticals for clinical use. Details on production and quality control of the currently available products, provided here will be of use to scientists involved in the development of these radiopharmaceuticals. 606 $aNuclear medicine$7Generated by AI 606 $aRadioisotopes in medical diagnosis$7Generated by AI 615 0$aNuclear medicine 615 0$aRadioisotopes in medical diagnosis 700 $aIAEA$01594159 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911008994903321 996 $aPain Palliation of Bone Metastases$94394268 997 $aUNINA